Novo Nordisk presented new data from the retrospective, observational SCORE study that assessed treatment with semaglutide ...
Wegovy was also associated with a lower risk of hospitalization for heart failure, cardiovascular-related death, and ...
The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...
A new sub-analysis of the SELECT trial data shows semaglutide 2.4 mg substantially reduces the burden of total cardiovascular ...
Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...
News-Medical.Net on MSN1d
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...
Not only does it combat diabetes and aid in weight loss, but it also safeguards heart health in all patients at high ...
Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...
risk reduction with use of semaglutide 2.4 mg in a real-world environment1 SCORE is a retrospective, observational analysis of 27,963 patients with obesity or overweight and established ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback